Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for human stroke has just received approval from the Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), an independent Medical Research Ethics Committee.
The trial will be conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, with screening beginning shortly and dosing expected to start in the fourth quarter of 2022.
With the center having previously led DMT studies, Algernon had initially retained the CHDR and its affiliated pharmacy at the Leiden University Medical Center to develop the IVF destined for the Phase 1 study. The partners then decided to move forward with an ethics and clinical trial application in order to advance the DMT stroke research program in the fastest manner possible.
The focus of the research is grounded in the findings of several preclinical studies which have already demonstrated this particular psychedelic helps mitigate tissue damage and promotes neurogenesis as well as structural and functional neural plasticity, all key factors involved in the brain’s ability to form and reorganize synaptic connections and therefore helping the brain heal …